Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro., PMID:40489497
Endocytosis Properties of GD2-Specific Antibodies in Tumor Cells., PMID:40367084
Ocular Toxicity in GD-2 Antibody Therapy: A Case Study., PMID:40247734
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial., PMID:39952926
GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214
Antibody-Dependent Cellular Cytotoxicity of iPS Cell-Derived Natural Killer T Cells by Anti-GD2 mAb for Neuroblastoma., PMID:39916425
GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8., PMID:39702399
Action Mechanisms of Exosomes Derived from GD3/GD2-Positive Glioma Cells in the Regulation of Phenotypes and Intracellular Signaling: Roles of Integrins., PMID:39684463
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma., PMID:39668192
Prospects of anti-GD2 immunotherapy for retinoblastoma., PMID:39620227
Tuning the Protonation Sensitivity of Weak Acidic Groups on a Zwitterionic Dendrimer for Selectively Targeting GD2-Overexpressed Tumor Cells in an Acidic Tumor Microenvironment., PMID:39481027
Immunoliposomes for Neuroblastoma: Review of the Past Experience and Design of a Novel Nanoparticle., PMID:39477321
GD2 in Breast Cancer: A Potential Biomarker and Therapeutic Target., PMID:39467630
Dual-labeled anti-GD2 targeted probe for intraoperative molecular imaging of neuroblastoma., PMID:39407274
Anti-OAcGD2 antibody in combination with ceramide kinase inhibitor mediates potent antitumor cytotoxicity against breast cancer and diffuse intrinsic pontine glioma cells., PMID:39395135
Niraparib Enhances and Synergizes with Ganglioside GD2 to Potentiate its Inhibitory Effect on Bladder Cancer Cells., PMID:39354757
High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy., PMID:39200906
Omalizumab for Treatment of Anti-GD2 Antibody-related Urticaria., PMID:39177945
Protocol for assessing GD2 on formalin-fixed paraffin-embedded tissue sections using immunofluorescence staining., PMID:39046881
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine., PMID:38932316
Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma., PMID:38904586
GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior., PMID:38866755
Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells., PMID:38736882
Silencing of the PHLDA1 leads to global proteome changes and differentiation pathways of human neuroblastoma cells., PMID:38495105
Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment-Drug Conjugates Carrying Maytansinoids DM1 and DM4., PMID:37886955
Biology of GD2 ganglioside: implications for cancer immunotherapy., PMID:37670947
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy., PMID:37444475
GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior., PMID:36993422
Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells., PMID:36674755
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial., PMID:36547975
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments., PMID:36497290
Apoptosis is responsible for the cytotoxic effects of anti-GD2 ganglioside antibodies and aurora A kinase inhibitors on human neuroblastoma cells., PMID:35810485
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors., PMID:35764367
Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies., PMID:35086947
Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849
Chemoenzymatic Synthesis of 9NHAc-GD2 Antigen to Overcome the Hydrolytic Instability of O-Acetylated-GD2 for Anticancer Conjugate Vaccine Development., PMID:34469031
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment., PMID:34367149
Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices., PMID:33912384
Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model., PMID:33858849
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells., PMID:33722905
Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma., PMID:33572900
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression., PMID:33326254
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma., PMID:33303017
The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL)., PMID:33271265
Development of a dinutuximab delivery system using silk foams for GD2 targeted neuroblastoma cell death., PMID:33252182
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer., PMID:33015525
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy., PMID:32958698
Gangliosides and Neuroblastomas., PMID:32726962
Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy., PMID:31982247
For research use only. Not for human or drug use.
